HEALTHCARE IN THE DEVELOPING WORLD - THE ROLE OF INTELLECTUAL PROPERTY. ODI: 12 February 2003
|
|
- Lydia Knight
- 5 years ago
- Views:
Transcription
1 HEALTHCARE IN THE DEVELOPING WORLD - THE ROLE OF INTELLECTUAL PROPERTY ODI: 12 February 2003
2 KEY QUESTIONS What role does IP play in the development of new drugs and vaccines for the developing world? Is IP a barrier to access to medicines?
3 DEVELOPING WORLD DISEASE (DDW) R&D: GSK S EXPERIENCE One of the largest portfolios of medicines for DDW Only company involved in R&D for both the prevention and treatment of HIV/AIDS, TB and malaria Around 30 projects and programmes of relevance to developing world Diseases of Developing World Unit Dedicated DDW R&D facility - Tres Cantos
4 IP AND R&D OF MEDICINES AND VACCINES FOR DDW Patents stimulate and underpin the R&D of new medicines and vaccines - no patents, no cures It is clear that to increase R&D expenditure on neglected diseases will require a continued commitment for protection of intellectual property. UK HLWG Report We need new medicines and vaccines Absence of IP will reduce incentive to undertake R&D IP alone will not guarantee R&D - it requires IP and a market
5 MEETING THE CHALLENGE OF R&D FOR DDW Traditional business model does not apply for DDW - no market, no return to incentivise private sector Public sector lacks necessary expertise A new partnership model is essential - PPPs
6 THE BENEFITS OF PPPs Private sector - brings technological, development, manufacturing and distribution expertise Public sector partners - help fund development costs and ensure that medicines get to people who need them Partnership approach encourages R&D and accelerates the product s uptake
7 THE CONCEPT IN ACTION LapDap (anti-malarial) ACW 135 vaccines (meningitis) Global Alliance for Vaccination and Immunisation Medicines for Malaria Venture MSF DNDi Leishmaniasis, African Tryp and Chagas next? Concentrate on the solution, not a perceived problem
8 IS IP A BARRIER TO ACCESS TO MEDICINES? >95% of drugs on WHO EML are not patented, but 30% of those who need them do not get them.
9 PATENTS ON EDL DRUGS IN AFRICA 18 countries - no EDL drugs patented (out of 308) 23 countries - 1 EDL drug patented (out of 308) 9 countries - 2 EDL drugs patented (out of 308) 1 country - 3 EDL drugs patented (out of 308)
10 IS IP A BARRIER TO ACCESS TO MEDICINES? >95% of drugs on WHO EML are not patented but 30% of those who need them do not get them. 3 million deaths p.a. caused by TB and malaria, but drugs are not patented
11 STATUS OF COMMUNICABLE DISEASES IN AFRICA DISEASE ANNUAL DEATHS # OF INFECTIONS % OF POSSIBLE PATENTS COST TO TREAT Malaria 472, million annual cases 4.5% $1 per patient course Diarrheal Disease 394, million (global) 0% Cents per treatment Tuberculosis 229, million annual cases 0.5% $11 per patient (6 month supply) Trypanosomiasis 35, ,000 0% Drug donated HIV/AIDS 1,700, million 21.6% $1-3 per day
12 IS IP A BARRIER TO ACCESS TO MEDICINES? >95% of drugs on WHO EML are not patented but 30% of those who need them do not get them. 3 million deaths p.a. caused by TB and malaria, but drugs are not patented Most ARVs not patented in most of Africa, but most patients who need them do not get them
13 ARV PATENTS IN 53 AFRICAN COUNTRIES Regimen d4t+ddi+ind DHHS guidelines Strongly recommended d4t+ddi+ind+rit Strongly recommended d4t+3tc+ind AZT+3TC+NEL d4t+ddi+efv 3TC+d4T+NEV ddi+d4t+nev Strongly recommended Strongly recommended Strongly recommended Recommended as alternative Recommended as alternative zero patents 51 (96.2%) 51 (96.2%) 19 (35.8%) 15 (28.3%) 52 (98.1%) 18 (34.0%) 28 (52.8%) <1 patent 52 (98.1%) 52 (98.1%) 52 (98.1%) 25 (47.2%) 52 (98.1%) 30 (56.6%) 52 (98.1%) Source: Attaran & Gillespie-White (2001). Journal of the American Medical Association 286:
14 IS IP A BARRIER TO ACCESS TO MEDICINES? >95% of drugs on WHO EML are not patented but 30% of those who need them do not get them. 3 million deaths p.a. caused by TB and malaria, but drugs are not patented Most ARVs not patented in most of Africa, but most patients who need them don t get them No patents in India
15 INDIA: A CASE STUDY Estimated HIV+ Estimated AIDS cases 3,800, ,000 Estimated patients on HAART Patents on ARV drugs Local pharmaceutical plants Indian companies producing ARVs ARVs exported by Indian companies less than 20, 000 around 3.5% 0 22, or more 2 10 or more 2 1. UN/WHO Press Reports
16 CONCLUSIONS Focus on IP as a barrier is misleading and counterproductive The causes of lack of access are complex and multifaceted Poverty is key Required response - all sectors of global society must work together in new kinds of partnerships to find new solutions
17 SHARED RESPONSIBILITIES - WHAT IS GSK DOING? R&D into diseases of the developing world Community Partnerships that promote effective healthcare in the developing world Not for profit pricing All ARVs and anti-malarials 63 countries 120 Supply Arrangements in 50 countries 3x increase in shipments in 2002 Pilot programme for wider product range Innovative solutions - voluntary licensing
18 Shared Responsibilities Funding agencies NGOs (Non governmental organizations) Developed country governments IMPROVED ACCESS TO MEDICINES Multilateral agencies (UN, WHO, WTO, World Bank, etc.) Developing country governments Media Pharmaceutical industry
19 ACCESS - MUCH ACHIEVED Global Fund established AAI treatment numbers increasing WHO Treatment Guidelines and prequalified suppliers list Progress on the 3P framework - UK High Level Working Group, EU Regulation Doha Declaration Possible $10bn from US.BUT MUCH MORE TO DO
20 ACHIEVING FURTHER PROGRESS IP is an easy target But it is crucial to development of new medicines and vaccines There are many factors affecting access Focus on the real causes and the real solutions
21 Intellectual property protection is key to bringing forward new medicines, vaccines and diagnostics urgently needed for the health of the world's poorest people. Kofi Annan UN Secretary-General
DEVELOPMENT. The European Union confronts HIV/AIDS, malaria and tuberculosis. A comprehensive strategy for the new millennium EUROPEAN COMMISSION
DEVELOPMENT The European Union confronts HIV/AIDS, malaria and tuberculosis A comprehensive strategy for the new millennium EUROPEAN COMMISSION DE 121 FEB 2004 A global challenge Every minute, 11 people
More informationUnited States House of Representatives. I am the Executive Director of the North America office
Rachel M. Cohen, Executive Director Drugs for Neglected Diseases initiative, North America Written Testimony, Outside Witness Hearing Subcommittee on State and Foreign Operations, Committee on Appropriations
More informationIncreasing people s access to essential medicines in developing countries: a framework for good practice in the pharmaceutical industry
Increasing people s access to essential medicines in developing countries: a framework for good practice in the pharmaceutical industry A UK Government policy paper March 2005 Increasing people s access
More informationChronic hepatitis C Building access into drug development: DNDi strategy
Chronic hepatitis C Building access into drug development: DNDi strategy July 2017 IAS Isabelle Andrieux-Meyer Head of HIV/HCV Clinical Programs Declaration of interests Isabelle Andrieux-Meyer from Drugs
More informationDRAFT UNICEF PROCUREMENT OF HIV/AIDS-RELATED SUPPLIES AND SERVICES
DRAFT UNICEF PROCUREMENT OF HIV/AIDS-RELATED SUPPLIES AND SERVICES April 2005 Summary: Millions of children in developing countries are affected by the HIV/AIDS pandemic. Despite significant international
More informationThe Value of Product Development Partnerships in Vaccine Innovation. Hansi J. Dean International AIDS Vaccine Initiative
The Value of Product Development Partnerships in Vaccine Innovation Hansi J. Dean International AIDS Vaccine Initiative The Product Development Partnership Model A non-profit partnership of public and
More informationThank you for the opportunity to submit testimony on the Fiscal Year (FY) 2014 State
Drugs for Neglected Diseases initiative, North America Jennifer Katz, Policy Director March 2013 Testimony to the Subcommittee on State and Foreign Operations, Committee on Appropriations United States
More informationResolution adopted by the General Assembly. [without reference to a Main Committee (A/62/L.39 and Add.1)]
United Nations General Assembly Distr.: General 7 March 2008 Sixty-second session Agenda item 47 Resolution adopted by the General Assembly [without reference to a Main Committee (A/62/L.39 and Add.1)]
More informationThe Global Fund & UNICEF Partnership
The Global Fund & UNICEF Partnership Prof Michel D. Kazatchkine Executive Director UNICEF Executive Board February 9 th, 2011 The Global Fund Millennium Development Goals 1. Eradicate extreme poverty and
More informationInnovation, Access and Use Department of Essential Medicines and Health Products WHO
MARKETS FOR QUALITY-ASSURED PRODUCTS Sarah Garner and Francisco Blanco Innovation, Access and Use Department of Essential Medicines and Health Products WHO 1 Objectives Indicate market needs for medicines
More informationREPORT FROM THE COMMISSION. Annual Report ( )
EUROPEAN COMMISSION Brussels, 18.12.2012 COM(2012) 775 final REPORT FROM THE COMMISSION Annual Report (-) on the application of Council Regulation (EC) No 953/2003 of 26 May 2003 to avoid trade diversion
More informationRAPID DIAGNOSIS AND TREATMENT OF MDR-TB
RAPID DIAGNOSIS AND TREATMENT OF MDR-TB FORMING PARTNERSHIPS TO STRENGTHEN THE GLOBAL RESPONSE TO MDR-TB - WHERE IT MATTERS MOST I am delighted that this initiative will improve both the technology needed
More informationPost-2015: Innovative Financing of HIV/AIDS. Travis Mitchell Economic Affairs Division
Post-2015: Innovative Financing of HIV/AIDS Travis Mitchell Economic Affairs Division High Burden (HIV/AIDS) Low Income countries will remain dependent on external funding for decades, creating major financial
More information2014 Towards an HIV Cure symposium Melbourne The Role of a Public-Private Partnership in HIV Cure
2014 Towards an HIV Cure symposium Melbourne The Role of a Public-Private Partnership in HIV Cure Mike McCune, MD, PhD University of California, San Francisco Cure Interventions that Can Be Used Around
More informationUN Panel Discussion Millennium Development Goals. Ajay Singh Senior Director Dr Reddy s Laboratories 07 July 2010
UN Panel Discussion Millennium Development Goals Ajay Singh Senior Director Dr Reddy s Laboratories 07 July 2010 1 A role for everyone. North Large branded companies Strong engine of innovation Almost
More informationHEALTH I AM 1. of MANY AND WELFARE INITIATIVES. SOUTH AFRICANS THAT HAVE BENEFITTED FROM ANGLO AMERICAN S
I AM 1 of MANY HEALTH SOUTH AFRICANS THAT HAVE BENEFITTED FROM ANGLO AMERICAN S AND WELFARE INITIATIVES. Bonsela Masina, new mum, with her daughter at Anglo American s Highveld Hospital, close to Greenside
More informationDiagnostics product development projects
Page 0 Diagnostics product development projects Smiljka de Lussigny Technical Officer, HIV UNITAID Copenhagen, 23 September 2013 Page 1 1 2 3 About UNITAID HIV diagnostics market UNITAID s current investment
More informationIntellectual Property Rights & Vaccines in Developing Countries
Intellectual Property Rights & Vaccines in Developing Countries by Dr. S.S.Jadhav President DCVMN Developing Country Vaccine Manufacturers Network DCVMN Formed in November 2000. 7 members steering committee.
More informationUNITAID AT 10: INNOVATION IN GLOBAL HEALTH
UNITAID AT 10: INNOVATION IN GLOBAL HEALTH THE ROLE OF UNITAID AND WHY IT MATTERS Turning the tables on HIV/AIDS, Tuberculosis and Malaria is one the biggest favours the world has done itself in a generation.
More informationThe power of innovation to save lives
Innovative Finance The power of innovation to save lives May 2013 The challenge Life or death for a young child too often depends on whether he is born in a country where vaccines are available or not.
More informationUNITAID (A new innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, TB and malaria)
UNITAID (A new innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, TB and malaria) OECD GLOBAL FORUM ON DEVELOPMENT (Paris, 7 th October 2008) 1 Jorge Bermudez, Executive-Secretary,
More informationPublic-private partnerships: an overview
Transactions of the Royal Society of Tropical Medicine and Hygiene (2005) 99S, S1 S8 Public-private partnerships: an overview Roy Widdus Initiative on Public-Private Partnerships for Health (IPPPH), Global
More informationThe Economic and Social Council, Recalling the United Nations Millennium Declaration13 and the 2005 World Summit Outcome, 1
Resolution 2010/24 The role of the United Nations system in implementing the ministerial declaration on the internationally agreed goals and commitments in regard to global public health adopted at the
More informationINTRODUCTION TO THE MEDICINES PATENT POOL
www.medspal.org TABLE OF CONTENTS 1. Introduction to the Medicines Patent Pool 2. Background on MedsPaL 3. What patent information is included in MedsPaL? 4. What licensing and data exclusivity information
More informationAn innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria
UNITAID An innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria ECOSOC Annual Ministerial Review (Regional Ministerial Meeting on Financing Strategies
More informationStrengthening efforts to improve access to and affordability of medicines and technologies in the prevention and control of NCDs
Strengthening efforts to improve access to and affordability of medicines and technologies in the prevention and control of NCDs Overview and summary of feedback 18-19 February 2015 Summary (from policy
More informationImproving access to medicines for patients in lower-income countries
Improving access to medicines for patients in lower-income countries AHBS II Dakar November 6, 2017 Our access strategy: tailoring our approach to income segments Income segments 1 High Income Upper-middle
More informationDEVELOPMENT. The EU confronts HIV/AIDS, malaria and tuberculosis EUROPEAN COMMISSION DE 131
DEVELOPMENT The EU confronts HIV/AIDS, malaria and tuberculosis EUROPEAN COMMISSION DE 131 AUG 2006 This brochure has been published in English and French by the European Commission, Directorate-General
More informationThe road towards universal access
The road towards universal access JAN 2006 Issues Paper Requests... that the UNAIDS Secretariat and its Cosponsors assist in facilitating inclusive, country-driven processes, including consultations with
More informationItem 4.7. Draft Global Health Sector Strategy for HIV,
Item 4.7 Draft Global Health Sector Strategy for HIV, 2011 2015 Context of EB Discussions Following the request to the Director General in resolution WHA63.19 to submit a WHO HIV/AIDS strategy for 2011
More informationRohit Malpani, Director Policy & Analysis Brussels, April 26, 2016.
Current challenges and opportunities for access to affordable medicines - a perspective from a medical humanitarian organisation Rohit Malpani, Director Policy & Analysis Brussels, April 26, 2016. Médecins
More informationMDR-TB: Medicine quality and rational use
MDR-TB: Medicine quality and rational use Hans V. Hogerzeil, MD, PhD, FRCP Edin Director, Essential Medicines and Pharmaceutical Policies WHO, Geneva 1 Can we rely on essential medicines against TB? (1)
More informationOn 24 May 2005 the Council (GAERC), in its formation of Development Ministers, adopted the conclusions in Annex I.
COUNCIL OF THE EUROPEAN UNION Brussels, 24 May 2005 9278/05 DEVGEN 92 RELEX 257 SAN 74 ONU 61 ACP 73 NOTE from : General Secretariat dated 24 May 2005 No. prev. doc. : 9085/05 DEVGEN 88 RELEX 238 SAN 62
More informationJaderson Lima, MD On behalf of François Bompart, MD
Challenges and Successes of the FACT Project through Innovative Partnerships for the Development of Artesunate Combination Therapies for Malaria 5º. ENIFarMed São Paulo Brazil August 2011 Public-private
More informationREPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH (RMNCH) GLOBAL AND REGIONAL INITIATIVES
Information Brief: REPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH (RMNCH) GLOBAL AND REGIONAL INITIATIVES Family Care International (FCI) developed this information brief as part of the Mobilising Advocates
More informationMichel BAIJOT Vice President, WW Business Development & Strategic Alliances
Technology Transfer and Vaccines: The GSK Experience WHO Workshop on Technology Transfer for Local Manufacturing Capacity of Vaccines Geneva, November 30th, 2010 Michel BAIJOT Vice President, WW Business
More information5 th Islamic Conference of Health Ministers. Resolution. Istanbul, Turkey November 2015 (5-7 Safar 1437H)
5 th Islamic Conference of Health Ministers Resolution Istanbul, Turkey 17-19 November 2015 (5-7 Safar 1437H) Draft Resolution No. 2/5-ICHM On Healthy Life Style, Prevention and Control of Communicable
More informationPRIVATE SECTOR DRIVEN PUBLIC-PRIVATE PARTNERSHIPS. Africa Health Business Symposium, 6 November 2017 Soraya Ramoul, Director, Novo Nordisk
PRIVATE SECTOR DRIVEN PUBLIC-PRIVATE PARTNERSHIPS Africa Health Business Symposium, 6 November 2017 Soraya Ramoul, Director, Novo Nordisk Health is essential for Sustainable Development Three key targets
More informationGAVI, THE VACCINE ALLIANCE
#vaccineswork GAVI, THE VACCINE ALLIANCE Partnerships for Health Outcomes Susan Brown July, 2017, New York Gavi/2012/Doune Porter www.gavi.org 1 ABOUT GAVI Gavi s mission: to save children s lives and
More informationASEAN Activities on Increasing Access to ARV and HIV Related Supplies
ASEAN Activities on Increasing Access to ARV and HIV Related Supplies Consultation on Integrating Prevention and Management of STI/HIV/AIDS into Reproductive, Maternal and Newborn Health Services and the
More information1. The World Bank-GAVI Partnership and the Purpose of the Review
1. The World Bank-GAVI Partnership and the Purpose of the Review 1.1 The new World Bank Group strategy makes a strong case for an expanded World Bank Group role in global and regional dialogue and collective
More informationWorking for an International Organization in Public-Private Partnership : The Global Fund to Fight AIDS, Tuberculosis and Malaria
Working for an International Organization in Public-Private Partnership : The Global Fund to Fight AIDS, Tuberculosis and Malaria Birgit Poniatowski Acting Manager, Board Relations Overview The Global
More informationWHO WIPO WTO Trilateral symposium
WHO WIPO WTO Trilateral symposium Public Health, Intellectual Property, and TRIPS at 20: Innovation and Access to Medicines : Learning from the Past, Illuminating the Future Access to Medicines: Achievements
More informationBetter Partner Health
4 Better Partner Health Building strategic partnerships with like-minded organizations, companies and government bodies better positions Mylan to reach patients and achieve our mission. From R&D to manufacturing
More informationVersion for the Silent Procedure 29 April Agenda item January Hepatitis
Version for the Silent Procedure 29 April 2014 134th session EB134.R18 Agenda item 10.5 25 January 2014 Hepatitis The Executive Board, Having considered the report on hepatitis, 1 RECOMMENDS to the Sixty-seventh
More informationGlobal health and vaccination: TB & beyond. Dr Mary Moran Executive Director
Global health and vaccination: TB & beyond Dr Mary Moran Executive Director mmoran@policycures.org Outline About Policy Cures 3 reasons to focus on vaccine innovation Where are we today? The pipeline Where
More informationTALKING POINTS INTRODUCTION
TALKING POINTS INTRODUCTION I have been asked by Amina to talk about health and development and to share some of the experiences of the GAVI Alliance model that might be replicated in furtherance of other
More informationMalaria Initiative: Access
Novartis Social Business Malaria Initiative: Access Improving affordability and availability of medicines Over the past decade, the Novartis Malaria Initiative has pioneered the pharmaceutical response
More informationHealth for Humanity 2020 Goals 2
2017 for Humanity Report Better for Humanity 2020 s 2 At Johnson & Johnson, we aspire to profoundly change the trajectory of health for humanity. Our for Humanity 2020 s, underpinned by 16 targets, focus
More informationMODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit
MODULE SIX Global TB Institutions and Policy Framework Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be Covered Global TB policy and coordinating structures The Stop TB Strategy TB/HIV collaborative
More informationNCDs in the Post-2015 Development Agenda
NCDs in the Post-2015 Development Agenda Regional Consultation on Multisectoral Policies for Prevention and Control of NCDs in the South-East Asia Region Bengaluru, India 18-20 August 2014 Jacob Kumaresan
More informationDirector-General, Mr Francis Gurry, honourable ministers, distinguished heads of agencies, distinguished delegates, ladies and gentlemen,
Dr Margaret Chan Director-General Strengthening multilateral cooperation on intellectual property and public health Address at the World Intellectual Property Organization Conference on Intellectual Property
More informationGAVI s Financing for Pneumococcal Vaccines, including the Advance Market Commitment
GAVI s Financing for Pneumococcal Vaccines, including the Advance Market Commitment Tania Cernuschi Third Regional Pneumococcal Symposium, Istanbul, 13th - 14th February 2008 1 The GAVI Alliance Public-private
More informationUNITED KINGDOM. In its recently-published document; UK Aid; Changing Lives, Delivering Results, DFID sets out its commitment to health.
UNITED KINGDOM 3.1 HEALTH FINANCING AND STRENGTHENING HEALTH SYSTEMS 3.1.1 We will continue our efforts towards the goal of providing at least a projected US$ 60 billion to fight infectious diseases and
More informationCOMMISSION OF THE EUROPEAN COMMUNITIES COMMUNICATION FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT
COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 27.04.2005 COM(2005) 179 final. COMMUNICATION FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT A European Programme for Action to Confront
More information39th Meeting of the UNAIDS Programme Coordinating Board Geneva, Switzerland. 6-8 December 2016
8 December 2016 39th Meeting of the UNAIDS Programme Coordinating Board Geneva, Switzerland 6-8 December 2016 Decisions The UNAIDS Programme Coordinating Board, Recalling that all aspects of UNAIDS work
More informationinnovative finance The GAVI Matching Fund A public-private partnership to save children s lives
innovative finance The GAVI Matching Fund A public-private partnership to save children s lives The challenge Abdul, Sierra Leone Abdul, a young boy in Sierra Leone, was one of the lucky ones. In June
More informationContextual overview with reference to MDG Goal 6 and projection for Post-2015
Contextual overview with reference to MDG Goal 6 and projection for Post-2015 10th Partnership Annual Conference Side Event Combating HIV and TB through a joint regional action Helsinki, Finland November
More informationTHE Price of a Pandemic 2017
THE Price of a Pandemic 2017 From 2000-2015: 33 million people died because of TB at a global economic cost of $617bn This report was produced the Global TB Caucus, an international network of over 2,000
More informationCOMMONWEALTH MINISTERS
COMMONWEALTH MINISTERS Reference Book 2012 Extract from the Commonwealth Ministers Reference Book featuring Britannia Industries Limited The enclosed is an extract from the Commonwealth Ministers Reference
More informationPost 2015 Agenda. Mike Battcock Civil Society Department
Post 2015 Agenda Mike Battcock Civil Society Department 1 Millennium Development Goals Progress The remaining task Post 2015 Agenda High Level Panel A million voices global conversation Next steps in negotiations
More informationUniting the world against AIDS
Uniting the world against AIDS A letter from Peter Piot, Executive Director For over 27 years, our world has been living with HIV. And in just this short time, AIDS has become one of the make-or-break
More informationOkinawa, Toyako, and Beyond: Progress on Health and Development
Okinawa, Toyako, and Beyond: Progress on Health and Development Prof. Michel D. Kazatchkine Executive Director The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations University, Tokyo,
More informationMALARIA VACCINE PILOTS
MALARIA VACCINE PILOTS BOARD MEETING Judith Kallenberg, Geneva Reach every child www.gavi.org Developments since 2013 (1/5) 2013 Malaria vaccine shortlisted in Vaccine Investment Strategy Board decision
More information1.2 Building on the global momentum
1.1 Context HIV/AIDS is an unprecedented global development challenge, and one that has already caused too much hardship, illness and death. To date, the epidemic has claimed the lives of 20 million people,
More informationStrategies to Control Pneumonia and Diarrhoea: Tackling the deadliest diseases for the world s poorest children
Strategies to Control Pneumonia and Diarrhoea: Tackling the deadliest diseases for the world s poorest children Dr. Mark W. Young Senior Health Specialist UNICEF Programme Division New York September 24,
More informationUN HIGH-LEVEL MEETING ON TB KEY TARGETS & COMMITMENTS FOR 2022
UN HIGH-LEVEL MEETING ON TB KEY TARGETS & COMMITMENTS FOR 2022 UNHLM ON TB KEY TARGETS FOR 2022 WE, HEADS OF STATE AND GOVERNMENT AND REPRESENTATIVES OF STATES AND GOVERNMENTS ASSEMBLED AT THE UNITED NATIONS
More informationEconomic and Social Council
United Nations E/CN.6/2010/L.6 Economic and Social Council Distr.: Limited 9 March 2010 Original: English ADOPTED 12 March 2010 ADVANCE UNEDITED VERSION Commission on the Status of Women Fifty-fourth session
More informationResolution adopted by the General Assembly on 11 September [without reference to a Main Committee (A/69/L.91 and Add.1)]
United Nations A/RES/69/325 General Assembly Distr.: General 6 October 2015 Sixty-ninth session Agenda item 12 Resolution adopted by the General Assembly on 11 September 2015 [without reference to a Main
More informationAccelerating progress towards the health-related Millennium Development Goals
Accelerating progress towards the health-related Millennium Development Goals The critical role of the national health policy & strategy in strengthening health systems and delivering effective interventions
More informationGlobal Health Policy Search results
Page 1 of 5 Global Health Policy Search results February 12, 2007 Incentives for Better Health around the World Posted by Ruth Levine Search Contact Us Site Map Home Initiatives Research Topics Publications
More informationBD-PEPFAR Labs for Life Partnership
BD-PEPFAR Labs for Life Partnership Renuka Gadde BD Global Health Jane Mwangi Division of Global HIV & TB, CDC Kenya FORUM ON PUBLIC-PRIVATE PARTNERSHIPS FOR GLOBAL HEALTH AND SAFETY October 27-28, 2016
More informationThe Crisis in. Vaccine Development
The Crisis in Vaccine Development Stanley A. Plotkin 1 Annecy 2015 The Evolution of the Vaccine Industry 1. 18 th -19 th Centuries Pioneers 2. 1900-1950 National Producers 3. 1960-1980 Globalization 4.
More informationStatement by Dr Marcos Espinal at the ECOSOC High-Level Segment, 6 July Madam President, Esteemed Delegates, Ladies and Gentlemen.
Statement by Dr Marcos Espinal at the ECOSOC High-Level Segment, 6 July 2009 Madam President, Esteemed Delegates, Ladies and Gentlemen. Many thanks for the opportunity to speak here today. I think the
More informationPrevention and control of hepatitis B and C in the European Region of WHO
Prevention and control of hepatitis B and C in the European Region of WHO Viral Hepatitis Prevention Board Dr Nedret Emiroglu WHO Regional Office for Europe Burden of viral hepatitis in the European Region
More informationTUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.
30 August 2007 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-seventh session Brazzaville, Republic of Congo, 27 31 August Provisional agenda item 7.8 TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE
More informationThe road towards universal access
The road towards universal access Scaling up access to HIV prevention, treatment, care and support 22 FEB 2006 The United Nations working together on the road towards universal access. In a letter dated
More informationTB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director
TB 2015 burden, challenges, response Dr Mario RAVIGLIONE Director Addis Ababa, Ethiopia 11-13 November 2015 Overview TB basics TB burden & challenges Response: End TB Strategy DAY 1 What is TB? Definition
More informationStrengthening Health Systems and Blood Services
Strengthening Health Systems and Blood Services through a Primary Health Care Approach Dr Neelam Dhingra Coordinator Blood Transfusion safety WHO-HQ, Geneva Outline of the Presentation Blood Transfusion
More informationBotswana Private Sector Health Assessment Scope of Work
Example of a Scope of Work (Botswana) Botswana Private Sector Health Assessment Scope of Work I. BACKGROUND The Republic of Botswana is a stable, democratic country in Southern Africa with an estimated
More informationCOUNCIL OF THE EUROPEAN UNION. Brussels, 24 November /04 DEVGEN 239 RELEX 575 SAN 190
COUNCIL OF THE EUROPEAN UNION Brussels, 24 November 2004 15158/04 DEVGEN 239 RELEX 575 SAN 190 NOTE from : the General Secretariat dated : 24 November 2004 No. prev. doc. : 14881/04 DEVGEN 224 RELEX 550
More informationAccess to Medicines in the Context of the Right to Health
Access to Medicines in the Context of the Right to Health An overview and WHO Perspective Human Rights Council SOCIAL FORUM 18 February 2015 Room XII, Palais des Nations, Geneva Zafar Mirza Public Health,
More informationAuthors: Jennifer Kates (Kaiser Family Foundation), José-Antonio Izazola (UNAIDS), Eric Lief (CSIS).
Financing the response to AIDS in low- and middleincome countries: International assistance from the G8, European Commission and other donor Governments, 2006 Authors: Jennifer Kates (Kaiser Family Foundation),
More informationProgress, challenges and the way forward in ASEAN Member States
MDG 6A: Combating HIV/AIDS Progress, challenges and the way forward in ASEAN Member States Dr Bob Verbruggen UNAIDS Regional Support Team ASEAN Multi-Sectoral Workshop on MDGs July 30-31 2012, Yangon,
More information2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services:
The theme for World TB Day 2014 is Reach the missed 3 million. Every year 3 million people who fall ill with TB are missed by health systems and do not always get the TB services that they need and deserve.
More informationViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV
ViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV ViiV Healthcare is a company 100% committed to HIV, and we are always looking to move beyond the status
More informationDriving access to medicine
Driving access to medicine An example from the Novartis Malaria Initiative Hans Rietveld Director, Market Access & Capacity Building Novartis Malaria Initiative Social Forum - Geneva February 20, 2015
More informationWHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES
WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES SURVEY QUESTIONNAIRE A.1. Introduction The Global Action Plan for Influenza Vaccines (GAP) was launched in 2006 as a ten year initiative to address the anticipated
More informationHIV in the world 2009
HIV in the world 2009 Joep M.A. Lange Center for Poverty-related Communicable Diseases Academic Medical Center / University of Amsterdam The failure of HIV prevention Despite positive trends, the
More informationABOUT. CIEL Healthcare Limited ( CHL ), a subsidiary of CIEL Limited, is a Mauritian registered private limited
FACTSHEET ABOUT CIEL Healthcare Limited ( CHL ), a subsidiary of CIEL Limited, is a Mauritian registered private limited company, with a prime objective to own, operate and manage assets in the healthcare
More informationinnovative finance The GAVI Matching Fund A public-private partnership to save children s lives
innovative finance The GAVI Matching Fund A public-private partnership to save children s lives August 2013 The challenge Abdul, a young boy in Sierra Leone, was one of the lucky ones. He was severely
More informationThe WHO END-TB Strategy
ENDING TB and MDR-TB The WHO END-TB Strategy Dr Mario RAVIGLIONE Director Joint GDI/GLI Partners Forum WHO Geneva, 27 April 2015 This talk will deal with TB Burden Progress, Challenges Way Forward Who
More informationEmergency Plan. Pink Ribbon Red. under President. With. screened and Significantly. Commitments: to catalyze. a dynamic, including. of shared.
Pink Ribbon Red Ribbon Overview Pink Ribbon Red Ribbon is an innovative partnership to leverage public and private investments in global health to combat cervical and breast cancer two of the leading causes
More informationHarnessing the power of vaccines using the public and private sector: A 21 st century model for international development
Harnessing the power of vaccines using the public and private sector: A 21 st century model for international development Dr. Seth Berkley, CEO GAVI Alliance Wellcome Trust Cambridge Centre for Global
More informationPatients First! Gilles Van Cutsem, MSF
Patients First! Patients First! Gilles Van Cutsem, MSF Access Campaign: 1999-2010 Bearing Witness We are not certain that by speaking we will necessarily be able to save lives, but we know for certain
More informationEU support to hepatitis research. Anna Lönnroth Sjödén Health Research DG Research - European Commission
EU support to hepatitis research Anna Lönnroth Sjödén Health Research DG Research - European Commission Hepatitis B and C Summit, Brussels, 15 October 2010 1 Main Objectives: to improve quality of life
More informationSIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/13 Provisional agenda item March Hepatitis
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/13 Provisional agenda item 12.3 28 March 2014 Hepatitis Improving the health of patients with viral hepatitis Report by the Secretariat 1. The Executive Board at
More informationGuidance on Matching Funds: Tuberculosis Finding the Missing People with TB
February 2017 Guidance on Matching Funds: Tuberculosis Finding the Missing People with TB 1. Background TB is the leading cause of death by infectious disease, killing 1.8 million people in 2015. Each
More informationREGIONAL COMMITTEE FOR AFRICA AFR/RC54/14 Rev June 2004
WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR AFRICA ORGANISATION MONDIALE DE LA SANTE BUREAU REGIONAL DE L AFRIQUE ORGANIZAÇÃO MUNDIAL DE SAÚDE ESCRITÓRIO REGIONAL AFRICANO REGIONAL COMMITTEE FOR AFRICA
More informationSuraj Madoori, Treatment Action Group, U.S. and Global Health Policy Director. On behalf of the Tuberculosis Roundtable
United States House of Representatives Committee on Appropriations Subcommittee on State and Foreign Operations and Related Programs Fiscal Year 2020 Written Testimony Suraj Madoori, Treatment Action Group,
More information